Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Open Access
- 5 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Chemistry
Abstract
The proteolysis targeting chimeras (PROTACs), which are composed of a target protein binding moiety, a linker, and an E3 ubiquitin ligase binder, have been a promising strategy for drug design and discovery. Given the advantages of potency, selectivity, and drug resistance over inhibitors, several PROTACs have been reported in literature, which mostly focus on noncovalent or irreversible covalent binding to the target proteins. However, it must be noted that noncovalent or irreversible PROTACs have several drawbacks such as weak binding affinity and unpredictable off-target effects. Reversible covalent PROTACs, with properties of enhanced potency, selectivity, and long duration of action, have attracted an increasing amount of attention. Here, we propose a comparison between these three patterns and highlight that reversible covalent PROTACs could pave the way for a wide variety of challenging target degradations.Keywords
This publication has 31 references indexed in Scilit:
- Structural basis of PROTAC cooperative recognition for selective protein degradationNature Chemical Biology, 2017
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting ChimerasACS Central Science, 2016
- Targeting biomolecules with reversible covalent chemistryCurrent Opinion in Chemical Biology, 2016
- Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligandBioorganic & Medicinal Chemistry, 2016
- Catalytic in vivo protein knockdown by small-molecule PROTACsNature Chemical Biology, 2015
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4Cell Chemical Biology, 2015
- Benchmarking in Vitro Covalent Binding Burden As a Tool To Assess Potential Toxicity Caused by Nonspecific Covalent Binding of Covalent DrugsChemical Research in Toxicology, 2013
- A complex task? Direct modulation of transcription factors with small moleculesCurrent Opinion in Chemical Biology, 2010
- Targeting transcription factors for therapeutic benefitMolecular BioSystems, 2008
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences of the United States of America, 2001